FDA Approves Donanemab for Early Symptoms of Alzheimer’s Disease
The approval follows positive data from the Phase 3 TRAILBLAZER-ALZ 2 clinical trial. According to Eli Lilly and Company, donanemab may help eliminate excessive amyloid plaque buildup and slow the progression of impairment related to a person’s ability to process new information or remember important dates, among other things.
The U.S. Food and Drug Administration (FDA) has approved the use of donanemab (350 mg/20 mL, monthly intravenous injection) from Eli Lilly and Company to treat adults with early-stage Alzheimer’s disease symptoms. This indication includes people… + more
Eli Lilly and Company Collaborates with OpenAI to Develop New Antimicrobial Drugs
The alliance will enable the use of generative artificial intelligence to develop personalized technologies to combat drug-resistant pathogens. + read more
QuickPen® preloaded with tirzepatide, which helps fight obesity and diabetes
The KwikPen is a pre-filled, multi-dose pen. It was first introduced to the market by Lilly in 2008 and is already used to administer various diabetes medications around the world. + read more
Mirikizumab Shows Promising Efficacy in Crohn’s Disease
The VIVID-1 study by Eli Lilly and Company shows that mirikizumab provides significant improvements in patients with Crohn’s disease, demonstrating efficacy in both bio-naive and treatment-naive patients. + read more
New agreement between Organon and Lilly to market two migraine drugs in Europe
Organon will have sole responsibility for the distribution and commercialization of Emgality® (galcanezumab) and RAYVOW™ (lasmiditan) in Europe, leveraging its commercial expertise in central nervous system diseases. + read more
Positive results of mirikizumab in moderate to severe Crohn’s disease
Results from the VIVID-1 study after 52 weeks of treatment demonstrate the efficacy of mirikizumab in achieving clinical remission and endoscopic response in patients with moderate to severe Crohn’s disease + read more
Progression of Pirtobrutinib in Adult Patients with CLL or PCLCL Pretreated with BTK Inhibitors
A publication in the New England Journal of Medicine (NEJM) provides additional clinical data to those presented at the 2022 American Society of Hematology (ASH) annual meeting + more.